G. Coukos

Discipline

History, Philosophy and Sociology of Sciences (10) Psychology (4) Economies and finances (2) Communication sciences (1)

Type

Articles (110) Reviews (21)

Co-author

Date

Source

Keyword

Cancer (66) Cancer (66) cancer (65) Immunotherapy (50) Immunotherapy (50) Human beings (46) Cells (46) Tumors (41) T cells (41) Patients (40) Patients (40) Tumors (38) Treatment (32) Mice (30) Therapeutics (29) Lymphocytes (28) therapy (25) Use (24) Expression (23) analysis (22) Analysis (22) novel (22) show (21) immunity (19) Immunity (19) Animals (19) Inhibitors (17) Peptides (17) protein (16) approach (16)

Documents written by G. Coukos (110) | is about G. Coukos (0)

Reflections on the opportunities and challenges of applying experience-based co-design (EBCD) to phase 1 clinical trials in oncology.
N. Graber et al.
Urolithin-A Promotes CD8+ T Cell-mediated Cancer Immunosurveillance via FOXO1 Activation.
P. Ginefra et al. (May 3, 2024)
PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells.
M. Morotti et al.
Combining SiRPα decoy-coengineered T cells and antibodies augments macrophage-mediated phagocytosis of tumor cells.
E. Stefanidis et al. (Apr 23, 2024)
B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma.
N. Gavrielatou et al.
Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient.
S. Anchisi et al. (Dec 31, 2023)
Machine learning methods and harmonized datasets improve immunogenic neoantigen prediction.
M. Müller et al. (Nov 14, 2023)
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma.
K. Homicsko et al.
Activation of the transcription factor NFAT5 in the tumor microenvironment enforces CD8+ T cell exhaustion.
L. Tillé et al.
A lentiviral vector for the production of T cells with an inducible transgene and a constitutively expressed tumour-targeting receptor.
P. Reichenbach et al.
Machine learning predictions of MHC-II specificities reveal alternative binding mode of class II epitopes.
J. Racle et al. (Jun 13, 2023)
Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors.
J. Schmidt et al. (Jun 6, 2023)
Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8+ T cells.
S.J. Carmona et al.
The immunopeptidome landscape associated with T cell infiltration, inflammation and immune editing in lung cancer.
A.I. Kraemer et al.
TCR sequencing and cloning methods for repertoire analysis and isolation of tumor-reactive TCRs.
R. Genolet et al. (Apr 24, 2023)
Towards next-generation TIL therapy: TILs enriched in neoepitope-specific T cells.
M. Arnaud et al.
Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
U.F. Röhrig et al.
Patient-reported outcomes in adoptive cell-therapy trials: mind the gap.
E. Ghisoni et al.
Low-dose irradiation for reversing immunotherapy resistance: how to translate?
J. Bourhis et al.
Deciphering the landscape of phosphorylated HLA-II ligands.
M. Solleder et al. (May 20, 2022)
Sensitive identification of neoantigens and cognate TCRs in human solid tumors.
M. Arnaud et al.
Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC.
J. Bourhis et al.
A cell-based phenotypic library selection and screening approach for the de novo discovery of novel functional chimeric antigen receptors.
J.K. Fierle et al. (Jan 21, 2022)
TEM1-targeting PEGylated PLGA shikonin nanoformulation for immunomodulation and eradication of ovarian cancer.
E.I. Matthaiou et al. (2022)
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.
F.G. Herrera et al.

next